Differential influences of peroxisome proliferator-activated receptorsγ and -α on food intake and energy homeostasis

Diabetes

Volumn 52, Issue 9, 2003, Pages 2249-2259

  Larsen, Philip J ^a,b   Jensen, Per Bo ^a   Sørensen, Rikke V ^a   Larsen, Leif Kongskov ^a   Vrang, Niels ^a   Wulff, Erik M ^c   Wassermann, Karsten ^c  

^a Rheoscience ^*  (Denmark)

^b CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

^c NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACETOACETIC ACID; FENOFIBRATE; KETONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; RAGAGLITAZAR; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY FAT; CONTROLLED STUDY; DOSE RESPONSE; ENERGY; ENERGY METABOLISM; FEEDING; FOOD INTAKE; HOMEOSTASIS; INSULIN SENSITIVITY; LIPID DIET; MALE; NONHUMAN; NUTRITION; OBESITY; PRIORITY JOURNAL; RAT; SUBCUTANEOUS FAT;

ADIPOSE TISSUE; ANIMALS; ANTILIPEMIC AGENTS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; EATING; ENERGY METABOLISM; GENE EXPRESSION; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HOMEOSTASIS; HYPOGLYCEMIC AGENTS; INSULIN; LIPIDS; LIVER; MALE; OBESITY; ORGAN SIZE; OXAZINES; PHENYLPROPIONATES; PROCETOFEN; RATS; RATS, MUTANT STRAINS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS; WEIGHT GAIN;

EID: 0041820128     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.52.9.2249     Document Type: Article

References (38)

1. Desvergne B, Wahli W: Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20:649-688, 1999
2. Wang YX, Lee CH, Tiep S, Yu RT, Ham J, Kang H, Evans RM: Peroxisome proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell 113:159-170, 2003
3. Akazawa S, Sun F, Ito M, Kawasaki E, Eguchi K: Efficacy of troglitazone on body fat distribution in type 2 diabetes. Diabetes Care 23:1067-1071, 2000
4. Kersten S: Peroxisome proliferator activated receptors and obesity. Eur J Pharmacol 440:223-234, 2002
5. Martens FM, Visseren FL, Lemay J, de Koning EJ, Rabelink TJ: Metabolic and additional vascular effects of thiazolidinediones. Drugs 62:1463-1480, 2002
6. Lefebvre AM, Laville M, Vega N, Riou JP, van Gaal L, Auwerx J, Vidal H: Depot-specific differences in adipose tissue gene expression in lean and obese subjects. Diabetes 47:98-103, 1998
7. Björntorp P: Metabolic implications of body fat distribution. Diabetes Care 14:1132-1143, 1991
8. Gabriely I, Ma XH, Yang XM, Atzmon G, Rajala MW, Berg AH, Scherer P, Rossetti L, Barzilai N: Removal of visceral fat prevents insulin resistance and glucose intolerance of aging: an adipokine-mediated process? Diabetes 51:2951-2958, 2002
9. Weber RV, Buckley MC, Fried SK, Kral JG: Subcutaneous lipectomy causes a metabolic syndrome in hamsters. Am J Physiol 279:R936-943, 2000
10. Kallen CB, Lazar MA: Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. Proc Natl Acad Sci U S A 93:5793-5796, 1996
11. De Vos P, Lefebvre AM, Miller SG, Guerre-Millo M, Wong K, Saladin R, Hamann LG, Staels B, Briggs MR, Auwerx J: Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma. J Clin Invest 98:1004-1009, 1996
12. Burant CF, Sreenan S, Hirano K, Tai TA, Lohmiller J, Lukens J, Davidson NO, Ross S, Graves RA: Troglitazone action is independent of adipose tissue. J Clin Invest 100:2900-2908, 1997
13. de Souza CJ, Eckhardt M, Gagen K, Dong M, Chen W, Laurent D, Burkey BF: Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes 50:1863-1871, 2001
14. Chaput E, Saladin R, Silvestre M, Edgar AD: Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. Biochem Biophys Res Commun 271:445-450, 2000
15. Mancini FP, Lanni A, Sabatino L, Moreno M, Giannino A, Contaldo F, Colantuoni V, Goglia F: Fenofibrate prevents and reduces body weight gain and adiposity in diet-induced obese rats. FEBS Lett 491:154-158, 2001
16. Lohray BB, Lohray VB, Bajji AC, Kalchar S, Poondra RR, Padakanti S, Chakrabarti R, Vikramadithyan RK, Misra P, Juluri S, Manudi NV, Rajagopalan R: (-)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid [(-)DRF 2725]: a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity. J Med Chem 44:2675-2678, 2001
17. Ye JM, Iglesias MA, Watson DG, Ellis B, Wood L, Jensen PB, Sorensen RV, Larsen PJ, Cooney GJ, Wassermann K, Kraegen EW: PPARalpha/gamma ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly. Am J Physiol Endocrinol Metab 284: E531-E540, 2003
18. Levin BE, Dunn-Meynell AA, Balkan B, Keesey RE: Selective breeding for diet-induced obesity and resistance in Sprague-Dawley rats. Am J Physiol 273: R725-R730, 1997
19. Wang Q, Dryden S, Frankish HM, Bing C, Pickavance L, Hopkins D, Buckingham R, Williams G: Increased feeding in fatty Zucker rats by the thiazolidinedione BRL 49653 (rosiglitazone) and the possible involvement of leptin and hypothalamic neuropeptide Y. Br J Pharmacol 122:1405-1410, 1997
20. Emilsson V, O'Dowd J, Wang S, Liu YL, Sennitt M, Heyman R, Cawthorne MA: The effects of rexinoids and rosiglitazone on body weight and uncoupling protein isoform expression in the Zucker fa/fa rat. Metabolism 49:1610-1615, 2000
21. Etgen GJ, Oldham BA, Johnson WT, Broderick CL, Montrose CR, Brozinick JT, Misener EA, Bean JS, Bensch WR, Brooks DA, Shuker AJ, Rito CJ, McCarthy JR, Ardecky RJ, Tyhonas JS, Dana SL, Bilakovics JM, Paterniti JR Jr, Ogilvie KM, Liu S, Kauffman RF: A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-α/γ agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models. Diabetes 51:1083-1087, 2002
22. Burkey BF, Dong M, Gagen K, Eckhardt M, Dragonas N, Chen W, Grosenstein P, Argentieri G, de Souza CJ: Effects of pioglitazone on promoting energy storage, not expenditure, in brown adipose tissue of obese fa/fa Zucker rats: comparison to CL 316,243. Metabolism 49:1301-1308, 2000
23. Auwerx J: PPARgamma, the ultimate thrifty gene. Diabetologia 42:1033-1049, 1999
24. Mandrup S, Lane MD: Regulating adipogenesis. J Biol Chem 272:5367-5370, 1997
25. Air EL, Strowski MZ, Benoit SC, Conarello SL, Salituro GM, Guan XM, Liu K, Woods SC, Zhang BB: Small molecule insulin mimetics reduce food intake and body weight and prevent development of obesity. 8:179-183, 2002
26. Guerre-Millo M, Gervois P, Raspe E, Madsen L, Poulain P, Derudas B, Herbert JM, Winegar DA, Willson TM, Fruchart JC, Berge RK, Staels B: Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem 275:16638-16642, 2000
27. Dumont M, Mauriege P, Bergeron J, Despres JP, Prud'homme D: Effect of a six month gemfibrozil treatment and dietary recommendations on the metabolic risk profile of visceral obese men. Int J Obes Relat Metab Disord 25:1136-1143, 2001
28. Costet P, Legendre C, More J, Edgar A, Galtier P, Pineau T: Peroxisome proliferator-activated receptor alpha-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis. J Biol Chem 273:29577-29585, 1998
29. Scharrer E: Control of food intake by fatty acid oxidation and ketogenesis. Nutrition 15:704-714, 1999
30. Meertens LM, Miyata KS, Cechetto JD, Rachubinski RA, Capone JP: A mitochondrial ketogenic enzyme regulates its gene expression by association with the nuclear hormone receptor PPARalpha. EMBO J 17:6972-6978, 1998
31. Langhans W, Egli G, Scharrer E: Selective hepatic vagotomy eliminates the hypophagic effect of different metabolites. J Auton Nerv Syst 13:255-262, 1985
32. Arase K, Fisler JS, Shargill NS, York DA, Bray GA: Intracerebroventricular infusions of 3-OHB and insulin in a rat model of dietary obesity. Am J Physiol 255:974-981, 1988
33. Lutz TA, Diener M, Scharrer E: Intraportal mercaptoacetate infusion increases afferent activity in the common hepatic vagus branch of the rat. Am J Physiol 273:R442-R445, 1997
34. Boutellier S, Lutz TA, Volkert M, Scharrer E: 2-Mercaptoacetate, an inhibitor of fatty acid oxidation, decreases the membrane potential in rat liver in vivo. Am J Physiol 277:R301-R305, 1999
35. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, Kuriyama H, Hotta K, Nakamura T, Shimomura I, Matsuzawa Y: PPAR-γ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50:2094-2099, 2001
36. Yang W-S, Lee W-J, Funahashi T, Tanaka S, Matsuzawa Y, Chao C-L, Chen C-L, Tai T-Y, Chuang L-M: Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 86:3815-3819, 2001
37. Berg AH, Combs TP, Scherer PE: ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. 13:84-89, 2002
38. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, Bihain BE, Lodish HF: Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A 98:2005-2010, 2001